TYRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tyra Biosciences Inc (TYRA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, positive clinical developments, and a bullish technical setup. Despite the slight pre-market dip, the long-term growth potential outweighs short-term fluctuations.
The technical indicators are bullish. The MACD is positive and contracting, RSI is neutral at 61.523, and the moving averages show a bullish alignment (SMA_5 > SMA_20 > SMA_200). Key support is at 26.509, and resistance is at 34.783, with the stock currently trading near resistance levels.
Strong analyst support with multiple price target increases and overweight/outperform ratings.
Positive clinical developments, including Phase 2 and Phase 3 data for dabogratinib, which has significant therapeutic potential.
Recent acceptance of abstracts at the ASCO GU Cancer Symposium, highlighting advancements in FGFR biology.
Bullish technical indicators and moving averages.
Pre-market price decline of -2.05%.
Lack of significant hedge fund or insider trading activity.
No recent congress trading data.
In Q3 2025, Tyra Biosciences reported a net income loss of -$29.87M, though this represents a 24.37% YoY improvement. EPS improved by 21.95% YoY to -0.5, but revenue remains at 0 due to the company's clinical-stage status.
Analysts are highly bullish on TYRA, with multiple firms initiating coverage or raising price targets. Recent price targets range from $42 to $59.62, reflecting confidence in the company's lead asset dabogratinib and its potential blockbuster opportunities in oncology and growth disorders.
